Preparation method of breast and menstruation regulating compound essential oil

Abstract

This invention belongs to the field of traditional Chinese medicine plant essential oil technology, specifically relating to a method for preparing a compound essential oil for regulating breast and menstruation. A compound essential oil is made from the following raw materials in parts by weight: 8-15 parts Artemisia argyi essential oil, 8-15 parts Pinus massoniana essential oil, 8-12 parts snake oil, 8-12 parts emu oil, 8-12 parts camellia seed oil, 3-8 parts cinnamon essential oil, 3-8 parts Ligusticum chuanxiong essential oil, 3-8 parts Angelica dahurica essential oil, 3-8 parts Curcuma zedoaria essential oil, 0.5-2 parts agarwood essential oil, 8-12 parts parsley seed essential oil, 8-12 parts chamomile essential oil, and 8-12 parts cypress essential oil. This invention scientifically combines various essential oils to organically integrate the effects of warming the meridians and dispelling cold, promoting blood circulation and removing blood stasis, regulating qi and relieving pain, and reducing inflammation and swelling. It can effectively improve the inflammatory state of breast tissue, relieve breast swelling and pain, and effectively relieve uterine spasmodic contractions during dysmenorrhea, providing a safe and effective natural solution for managing menstrual pain.

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine plant essential oil technology, specifically relating to a method for preparing a compound essential oil for regulating mammary glands and menstruation. Background Technology

[0002] Breast hyperplasia, breast tenderness, and dysmenorrhea are common health problems among women of childbearing age, and their incidence is increasing year by year. Modern medical research shows that breast hyperplasia is closely related to endocrine disorders and abnormal estrogen levels; dysmenorrhea is mainly caused by increased prostaglandin secretion leading to uterine smooth muscle spasms. Currently used clinical treatments have problems such as side effects and unstable efficacy.

[0003] Traditional Chinese medicine essential oils, as a combination of traditional medicine and modern pharmaceutical technology, have the advantages of being natural, safe, and having few side effects. Artemisia argyi essential oil has the effects of warming the meridians and dispelling cold, removing dampness and relieving pain; Pinus massoniana essential oil has the effects of clearing heat and dispelling wind, detoxifying and relieving itching; Cinnamomum cassia essential oil can warm the meridians and promote blood circulation; Ligusticum chuanxiong essential oil can invigorate blood and promote qi circulation; snake oil and emu oil have good skin penetration-enhancing effects. However, the efficacy of single essential oil components is limited, and the transdermal absorption effect is not ideal. Therefore, it is necessary to develop a safe, effective, and transdermal-absorbable compound essential oil for regulating breast and menstrual cycles through scientific formulation and synergistic effects. Summary of the Invention

[0004] The purpose of this invention is to provide a method for preparing a compound essential oil for regulating breast and menstruation, so as to solve the problems existing in the prior art.

[0005] To achieve the above objectives, the present invention provides the following technical solution: A compound essential oil is made from the following raw materials in parts by weight: 8-15 parts Artemisia argyi essential oil, 8-15 parts Pinus massoniana essential oil, 8-12 parts snake oil, 8-12 parts emu oil, 8-12 parts camellia seed oil, 3-8 parts cinnamon essential oil, 3-8 parts Ligusticum chuanxiong essential oil, 3-8 parts Angelica dahurica essential oil, 3-8 parts Curcuma zedoaria essential oil, 0.5-2 parts agarwood essential oil, 8-12 parts parsley seed essential oil, 8-12 parts chamomile essential oil, and 8-12 parts cypress essential oil.

[0006] Furthermore, it is made from the following raw materials in parts by weight: 10 parts Artemisia argyi essential oil, 10 parts Pinus massoniana essential oil, 10 parts snake oil, 10 parts emu oil, 10 parts camellia seed oil, 5 parts cinnamon essential oil, 5 parts Ligusticum chuanxiong essential oil, 5 parts Angelica dahurica essential oil, 5 parts Curcuma zedoaria essential oil, 1 part agarwood essential oil, 10 parts parsley seed essential oil, 10 parts chamomile essential oil, and 10 parts cypress essential oil.

[0007] The present invention also provides the application of the compound essential oil in the preparation of drugs or cosmetics for relieving breast hyperplasia, breast tenderness, and dysmenorrhea.

[0008] Furthermore, the relief of breast hyperplasia is manifested by softening of breast lumps, reduction of swelling and pain, and shrinkage of lump size.

[0009] Furthermore, the relief of dysmenorrhea is manifested by a decrease in pain scores during menstruation, normalization of menstrual periods, and normalization of menstrual flow.

[0010] The present invention also provides a method for preparing the compound essential oil, comprising the following steps: S1. Add snake oil, emu oil and camellia seed oil to a brown glass container, and add the remaining essential oils one by one while stirring at 200-300 rpm for 1-2 minutes; S2. After all the essential oils have been added, continue stirring for 30-60 minutes, keeping the temperature at 25±2℃. S3. Seal the container and let it mature at room temperature for 18-32 hours, inverting and mixing once every 4 hours during this period; S4. After maturation, filter the solution using a 0.22μm filter membrane, collect the filtrate, and seal it under nitrogen gas for storage.

[0011] Furthermore, in step S1, the remaining essential oils are added in the following order: Artemisia argyi essential oil, Pinus massoniana essential oil, Cinnamomum cassia essential oil, Ligusticum chuanxiong essential oil, Angelica dahurica essential oil, Curcuma zedoaria essential oil, Agarwood essential oil, Parsley seed essential oil, Chamomile essential oil, and Cypress essential oil; stir for 1-2 minutes after adding each essential oil.

[0012] The compatibility principle of each component in this invention is as follows: The principal ingredients are Artemisia argyi essential oil and Pinus massoniana essential oil, which work together to warm the meridians and clear heat. Assistant herbs: Cinnamon essential oil, Ligusticum chuanxiong essential oil, Angelica dahurica essential oil, and Curcuma zedoaria essential oil assist the principal herbs to enhance their effects of warming the meridians and promoting blood circulation, dispelling wind and drying dampness, and breaking up blood stasis and eliminating accumulations; Adjuvant ingredients: Agarwood essential oil promotes qi circulation and relieves pain; snake oil and emu oil promote transdermal absorption and repair the skin barrier; camellia seed oil serves as a base carrier oil, enhancing the stability and lubricity of the complex system. Ingredients: Parsley seed oil promotes diuresis and eliminates dampness; chamomile oil has anti-inflammatory and soothing properties; cypress oil has astringent and regulatory effects.

[0013] Compared with the prior art, the present invention has the following beneficial effects: (1) This invention combines the effects of warming the meridians and dispelling cold, promoting blood circulation and removing blood stasis, regulating qi and relieving pain, and anti-inflammatory and swelling-reducing by scientifically combining various functional essential oils. The transdermal absorption rate is better than that of single essential oils.

[0014] (2) The compound essential oil of the present invention has significant anti-inflammatory activity. In the LPS-induced RAW264.7 macrophage inflammation model, the NO content at 100 μg / mL decreased to 5.9±0.5 μmol / L, which was 68.3% lower than that in the LPS model group (18.6±1.5 μmol / L), and was comparable to that of the positive control dexamethasone (5.2±0.4 μmol / L). At the same concentration, the inhibitory effect of the single essential oil was significantly weaker than that of the compound essential oil of the present invention, indicating that there is a significant synergistic effect among the active ingredients, which can effectively improve the inflammatory state of breast tissue and relieve breast swelling and pain.

[0015] (3) The compound essential oil of this invention has a significant inhibitory effect on oxytocin-induced contraction of isolated uterine smooth muscle in a dose-dependent manner. At a high concentration of 1.0 mg / mL, the contraction amplitude decreased from 3.52±0.28 g in the model group to 0.77±0.06 g, with an inhibition rate of 78.3%, which is close to the effect of the positive control atropine. At a medium concentration of 0.5 mg / mL, the inhibition rate was 62.5%, and at a low concentration of 0.1 mg / mL, the inhibition rate was 38.2%, showing a good dose-response relationship. It can effectively relieve uterine spasmodic contractions during dysmenorrhea and provide a safe and effective natural solution for the management of menstrual pain. Detailed Implementation

[0016] The technical solution of this invention patent will be clearly and completely described below. Obviously, the described embodiments are some embodiments of this invention, but not all embodiments.

[0017] 1. Materials and Methods 1.1 Formulation Composition 10g Artemisia argyi essential oil, 10g Pinus massoniana essential oil, 10g snake oil, 10g emu oil, 10g camellia seed oil, 5g cinnamon essential oil, 5g Ligusticum chuanxiong essential oil, 5g Angelica dahurica essential oil, 5g Curcuma zedoaria essential oil, 1g agarwood essential oil, 10g parsley seed essential oil, 10g chamomile essential oil, 10g cypress essential oil.

[0018] 1.2 Preparation method S1. Add snake oil, emu oil and camellia seed oil to a brown glass container. While stirring at 250 rpm, add artemisia essential oil, pine essential oil, cinnamon essential oil, chuanxiong essential oil, angelica essential oil, turmeric essential oil, agarwood essential oil, parsley seed essential oil, chamomile essential oil and cypress essential oil in sequence, stirring for 1-2 minutes after adding one essential oil at a time. S2. After all the essential oils have been added, continue stirring for 45 minutes, keeping the temperature at 25±2℃; S3. Seal the container and let it mature at room temperature for 24 hours, inverting and mixing once every 4 hours during this period; S4. After maturation, filter the solution using a 0.22μm filter membrane, collect the filtrate, purge with nitrogen, store at 4°C, and protect from light in a sealed container.

[0019] 1.3 Franz diffusion cell transdermal absorption test The transdermal absorption properties of the compound essential oils were evaluated using the Franz diffusion cell method and compared with those of individual essential oils and a positive control.

[0020] Abdominal skin was collected from SD rats (half male and half female, 200-250g, SPF grade), and subcutaneous fat and fascia were removed. The skin was placed between the supply and receiving cells of a Franz diffusion cell, with the stratum corneum facing the supply cell. 7 mL of PBS buffer (pH 7.4) was added to the receiving cell, and the mixture was incubated in a 32±0.5°C water bath with magnetic stirring at 300 rpm. 1 mL of the sample to be tested (see Table 2 for details) was added to the top of the supply cell, ensuring the sample completely covered the skin surface. The supply cell lid was then closed to prevent evaporation, and the sample addition time (t=0) was recorded. 1 mL samples were taken at 0.5, 1, 2, 4, 6, 8, 12, and 24 hours, with 1 mL of fresh PBS buffer added simultaneously. The liquid in the receiving cell was thoroughly mixed before sampling. The concentration of the active ingredient in the receiving solution at each time point was determined by HPLC, and the cumulative permeation (Qn, μg / cm³) was calculated. 2 Steady-state permeation rate (Jss, μg / cm³) 2 / h), the results are shown in Table 1-2.

[0021]

[0022] Table 1. Results of transdermal absorption tests for different formulations

[0023] Table 2. Transdermal absorption test data of different formulations over time.

[0024] As shown in Tables 1 and 2, the cumulative penetration of the compound essential oil of this invention over 24 hours is 68.9 ± 5.7 μg / cm³. 2 The steady-state permeation rate is 2.98 ± 0.25 μg / cm³. 2 / h, and significantly better than base oil and comparative examples 1-3.

[0025] 1.4 RAW264.7 Cell Anti-inflammatory Assay Lipopolysaccharide (LPS) induces nitric oxide (NO) production in RAW264.7 macrophages, and the anti-inflammatory activity of the samples was evaluated by measuring the NO inhibition rate. Griess reagent and NO2... - The reaction produces a purple-red product with maximum absorption at 540 nm. The complete culture medium consisted of 89% DMEM high-glucose medium, 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin antibiotics.

[0026] RAW264.7 cells in the logarithmic growth phase were harvested at a concentration of 5 × 10⁻⁶ cells / year. 4 Inoculate 100 μL per well into 96-well plates at a density of 1 / mL and incubate at 37°C and 5% CO2 for 24 h. Discard the culture medium, wash once with PBS buffer, and then add different concentrations of samples according to the groups: blank group (complete culture medium), LPS model group (complete culture medium + LPS 1 μg / mL), positive control group (dexamethasone 10 μg / mL + LPS 1 μg / mL), single essential oil group (Artemisia argyi essential oil / Pinus massoniana essential oil 100 μg / mL + LPS 1 μg / mL), and sample group (compound essential oil of this invention 6.25-100 μg / mL + LPS 1 μg / mL). After 24 h of incubation, collect the supernatant and determine the NO content using the Griess method. The results are shown in Table 3.

[0027] Table 3. Results of anti-inflammatory assays on RAW264.7 cells with different formulations.

[0028] As shown in Table 3, the compound essential oil of this invention has a significant inhibitory effect on LPS-induced NO production in RAW264.7 macrophages. At a concentration of 100 μg / mL, the NO content decreased to 5.9 ± 0.5 μmol / L, while at the same concentration, the NO content of Artemisia argyi essential oil was 12.6 ± 1.1 μmol / L and that of Pinus massoniana essential oil was 15.3 ± 1.2 μmol / L. The NO inhibition effect of the compound essential oil was significantly better than that of the individual essential oils and comparable to that of the positive control dexamethasone (5.2 ± 0.4 μmol / L), indicating that the compound essential oil of this invention has good anti-inflammatory activity and a significant synergistic effect.

[0029] 1.5 Inhibition test of isolated uterine smooth muscle The relaxation effect of compound essential oils on uterine smooth muscle was evaluated through an in vitro uterine smooth muscle contraction experiment, providing support for relieving dysmenorrhea.

[0030] Non-pregnant adult female SD rats were pretreated with estradiol 0.1 mg / kg intraperitoneally for 48 h. After euthanasia by cervical dislocation, a 2-3 cm segment of the mid-uterine horn was harvested and placed in oxygenated Krebs-Henseleit (KH) nutrient solution. Both ends of the specimen were ligated; the upper end was connected to a tension transducer, and the lower end was fixed in a bath containing (KH) nutrient solution. The environment was maintained at 37°C and saturated with a mixture of 95% O2 and 5% CO2. A preload of 1g was administered and stabilized for 30 min. After the contraction amplitude stabilized (variation <10%), the baseline contraction amplitude was recorded. Oxytocin (final concentration 10⁻⁸ M) was added to induce uterine contractions. After the contractions reached steady state (approximately 5 min), the contraction amplitude was recorded as the model group. Using the cumulative concentration dosing method, the following concentrations were added sequentially: 0.01 mg / mL, 0.05 mg / mL (cumulative), 0.1 mg / mL (cumulative), 0.5 mg / mL (cumulative), and 1.0 mg / mL (cumulative). The contraction amplitude was recorded after each dose was applied for 5 min. The data were processed, and the inhibition rate was calculated. The results are shown in Table 4.

[0031]

[0032] Table 4 Results of in vitro uterine smooth muscle inhibition test with different formulations

[0033] As shown in Table 4, the compound essential oil of this invention has a significant inhibitory effect on oxytocin-induced contraction of isolated uterine smooth muscle in a dose-dependent manner. At a high concentration (1 mg / mL), the contraction amplitude decreased from 3.52 ± 0.28 g in the model group to 0.77 ± 0.06 g, with an inhibition rate of 78.3%, which is close to that of the positive control atropine (inhibition rate 85.2%). This indicates that the compound essential oil has a significant uterine smooth muscle relaxation effect and can provide effective support for relieving dysmenorrhea.

[0034] The foregoing description of specific exemplary embodiments of the invention is for illustrative and explanatory purposes. These descriptions are not intended to limit the invention to the precise forms disclosed, and it will be apparent that many changes and variations can be made in accordance with the foregoing teachings. The exemplary embodiments were chosen and described in order to explain the specific principles of the invention and its practical application, thereby enabling those skilled in the art to implement and utilize various different exemplary embodiments of the invention, as well as various different choices and variations. The scope of the invention is intended to be defined by the claims and their equivalents.

Claims

1. A compound essential oil, characterized in that, It is made from the following raw materials in parts by weight: 8-15 parts Artemisia argyi essential oil, 8-15 parts Pinus massoniana essential oil, 8-12 parts snake oil, 8-12 parts emu oil, 8-12 parts camellia seed oil, 3-8 parts cinnamon essential oil, 3-8 parts Ligusticum chuanxiong essential oil, 3-8 parts Angelica dahurica essential oil, 3-8 parts Curcuma zedoaria essential oil, 0.5-2 parts agarwood essential oil, 8-12 parts parsley seed essential oil, 8-12 parts chamomile essential oil, and 8-12 parts cypress essential oil.

2. The compound essential oil according to claim 1, characterized in that, It is made from the following ingredients in parts by weight: 10 parts Artemisia argyi essential oil, 10 parts Pinus massoniana essential oil, 10 parts snake oil, 10 parts emu oil, 10 parts camellia seed oil, 5 parts cinnamon essential oil, 5 parts Ligusticum chuanxiong essential oil, 5 parts Angelica dahurica essential oil, 5 parts Curcuma zedoaria essential oil, 1 part agarwood essential oil, 10 parts parsley seed essential oil, 10 parts chamomile essential oil, and 10 parts cypress essential oil.

3. The use of the compound essential oil according to any one of claims 1-2 in the preparation of a medicine or cosmetic for relieving breast hyperplasia, breast tenderness, and dysmenorrhea.

4. The application according to claim 3, characterized in that, The relief of breast hyperplasia is manifested by softening of breast lumps, reduction of swelling and pain, and shrinkage of lump size.

5. The application according to claim 3, characterized in that, The relief of dysmenorrhea is manifested by a decrease in pain score during menstruation, normalization of menstrual period, and normalization of menstrual flow.

6. A method for preparing the compound essential oil according to any one of claims 1-2, characterized in that, Includes the following steps: S1. Add snake oil, emu oil and camellia seed oil to a brown glass container, and add the remaining essential oils one by one while stirring at 200-300 rpm for 1-2 minutes; S2. After all the essential oils have been added, continue stirring for 30-60 minutes, keeping the temperature at 25±2℃. S3. Seal the container and let it mature at room temperature for 18-32 hours, inverting and mixing once every 4 hours during this period; S4. After maturation, filter the solution using a 0.22μm filter membrane, collect the filtrate, and seal it under nitrogen gas for storage.

7. The preparation method according to claim 6, characterized in that, In step S1, the remaining essential oils are added in the following order: Artemisia argyi essential oil, Pinus massoniana essential oil, Cinnamomum cassia essential oil, Ligusticum chuanxiong essential oil, Angelica dahurica essential oil, Curcuma zedoaria essential oil, Agarwood essential oil, Parsley seed essential oil, Chamomile essential oil, and Cypress essential oil; stir for 1-2 minutes after adding each essential oil.

Images